

Request under Freedom of Information Act 2000 – our ref: FOI 19/20_344

I write in response to your request under the Freedom of Information (FOI) Act.

I confirm that the Trust holds the information you requested. Please see the replies, set out against your questions:

1. *In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently having treatment?*

We have 700 patients with a diagnosis of MS.

2. *Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS?*

The Trust has estimated that the time needed to respond to this request would exceed the 18 hours allowed for an FOI request. In this case the Trust is not obliged by the Freedom of Information Act 2000 to respond to your request (see section 12(1)).

3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the last 6 months. If you could, please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. patients treated with Lemtrada, Mavenclad, Ocrevus).

See below.

- 4 Could you please provide the total number of patients being treated with the following drugs:

Aubagio (teriflunomide) **34**

Avonex (interferon beta-1a) **8**

Betaferon (interferon beta-1b) **0**

rabio (glatiramer acetate) **0**

Copaxone (glatiramer acetate) **32**

Extavia (beta interferon-1b) * **5 or less**

Gilenya (fingolimod) **12**

Lemtrada (alemtuzumab) **23**

Mavenclad (cladribine) **0**

Ocrevus (Ocrelizumab) **0**

Plegridy (Peginterferon beta-1a) **9**

Rebif (beta interferon-1a) **28**

Tecfidera (dimethyl fumarate) **48**

Tysabri (natalizumab) **18**

Zinbryta (daclizumab) **0**

Ampyra (Fampyra) **0**

Ozanimod **0**

